MaxxNeuro 75 Ampharco treatment of nerve pain, local epilepsy (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Pregabalin

Ingredient

Composition information	Content
Pregabalin	75mg

Uses

indications

Treatment of neurological pain in peripheral neuropathy.

Treatment of pain here after the herpes virus infection. Support treatment for adult patients with local epilepsy.

Treatment of body aches (muscle fibrosis).

Treatment of nerve pain in spinal cord damage.

Pharmacology

Pregabalin connects high affinity into the location of Alpha2-Delta (1 sub-unit of calcium channel gate dependent) in the tissues of the central nervous system. This may be related to pain relief in pain and anti -convulsions on animabalin animals. On animal nerve damage models, pregabalin is found to reduce the release of calcium dependence of neurotransmitters before the painful receptor in the spinal cord, maybe by breaking the transportation through the calcium channel with alpha2-delta units and/or reducing calcium lines. Evidence from the models of nerve damage and persistent pain in other animals suggesting an analgesic pain through the pain receptor of Pregabalin may also intermediate intermediaries with the downward path of Noradrenergic and Serotonergic from the brain stem, regulating the sensory transmission in the spinal cord. Although Pregabalin is a structural derivative from the Gamma Aminobutyric Acid (GABA), it does not directly attach directly to the receptors of GABAA, GABAB, or Benzodiazepine, do not increase the response of GABAA, in implanted neurosus, unchanged Gabaa concentration in the brain or acute effects on the acquisition or recession However, the long -term cohesion of pregabalin into the implanted nerve cell increases the density of gaba specialized proteins and increases the speed of GABA function.

Dynamic pharmacokinetics

Pregabalin is well absorbed after oral, the peak concentration in plasma is achieved after 1.5 hours. Pregabalin's oral bioactivity is ≥ 90% and does not depend on the dose. Stable status is achieved in 24-48 hours after the dose is repeated. Pregabalin's absorption rate is reduced when used with food, leading to CMAX decreased by about 25-30% and lasting TMAX to about 3 hours. However, using pregabalin along with food has no effects on the total clinical pregabalin absorption. Therefore, Pregabalin can drink when hungry or with food.

Pregabalin is not associated with plasma proteins. In humans, Pregabalin's apparent distribution volume after oral use is about 0.5 l/kg. Pregabalin is the substrate for the L -system transportation that is responsible for transporting large amino acids through the brain blood barrier. Although there is no data in humans, pregabalin people have passed through the bloody barrier in the rats, rats and monkeys. In addition, pregabalin passes the placenta in the rat and appears in the milk of pregnant mice.

Pregabalin is insignificant metabolized in the human body, about 90% of the dose found in urine is Pregabalin in constant form. Pregabalin's n-methylate derivatives, Pregabalin's main metabolites are found in urine, accounting for about 0.9% of the dose.

Pregabalin is except for the circulatory system mainly due to the excretion through the kidneys in the form of unchanged with an average selling time of 6.3 hours in normal kidney functional people. The average clearance is about 67.0 to 80.9 ml/minute in healthy young people. Pregabalin elimination is almost proportional to creatinine clearance (CLCR). Reducing the dose in patients with kidney dysfunction or hemolysis is necessary. Pregabalin is eliminated from the plasma effectively by hemolysis.

Before taking MaxxNeuro 75 Ampharco treatment of nerve pain, local epilepsy (3 blisters x 10 tablets)

How to use

maxxneuro is taken with food or not. When stopping treatment with MaxxNeuro, it is necessary to stop slowly for a minimum of 1 week.

Dosage

Neurological pain in peripheral neuropathy due to diabetes

The maximum recommended dose of MaxxNeuro is 100 mg, 3 times/day (300 mg/day) in patients with a minimum creatinine clearance of 60 ml/min. Starting at a dose of 50 mg used 3 times /day (150 mg /day). Dosage may increase after 1 week of treatment depending on the response of patients up to 300 mg/day.

Neuropathy after the herpes virus infection

Maxxneuro's recommended dose is 75 dén 150 mg, 2 times/day, or 50 to 100 mg, 3 times/day (150 to 300 mg/day) on patients with a minimum creatinine clearance of 60 ml/minute.

Start at a dose of 75 mg, 2 times/day, or 50 mg, 3 times/day (150 mg/day). The dose increases after 1 week of treatment depending on the response of the patient to 300 mg/day. Patients do not relieve much pain after 2 to 4 weeks of treatment at a dose of 300 mg/day, and can tolerate MaxxNeuro, can increase the dose to 300 mg, 2 times/day, or 200 mg, 3 times/day (600 mg/day).

Support therapy for adult patients with local epilepsy

Proposing patients to start the total daily dose does not exceed 150 mg/day (75 mg, 2 times/day, or 50 mg, 3 times/day).

Dosage can increase after 1 week of treatment depending on the response of patients up to 300 mg/day and after another week, it may increase to the dark dose of 600 mg/day.

Treatment of body aches (muscle fibrosis)

Maxxneuro's recommended dose for body aches and pains is 300 to 450 mg/day.

Start at a dose of 75 mg, 2 times/day (150 mg/day). Dosage may increase after 1 week of treatment depending on the response of patients up to 150 mg 2 times/day (300mg/day).

Patients must reduce pain in a dose of 300 mg/day, which may increase the dose to 225 mg, 2 times/day (450 mg/day).

Although Pregabalin has been studied at a dose of 600 mg/day, there is no evidence that this dose is beneficial for patients and this dose is less tolerated.

Treatment of nerve pain in spinal cord injury

The initial recommended dose is 75 mg, 2 times/day (150 mg/day). The dose may increase after 1 week of treatment depending on the response of patients up to 150 mg 2 times/day (300 mg/day).

Patients do not relieve much pain after 2 to 3 weeks of treatment at a dose of 150 mg twice a day, and can tolerate MaxxNeuro can increase the dose to 300 mg, 2 times/day.

Patients with renal failure:

Table 1. Adjust the dose of pregabalin by kidney function.

Dose reduction in patients with renal dysfunction is necessary.

Creatinine clearance

(CLCR) (ml/min)

Total daily Pregabalin dose (mg/day)* Treatment regimen Time/day Time/day

15-30 25-50 75 150 150 150 1 or 2 times/day width = "12%"> 50-75 75 1 time/day

Patients under the single dose regimen 25 mg/day: take 1 additional dose of 25 mg or 50 mg

Patients under the single dose regimen 25-50 mg/day: take 1 additional dose of 50 mg or 75 mg

Patients under the single dose regimen of 50-75 mg/day: take 1 additional dose of 75 mg or 100 mg

Patients under the single dose regimen 75 mg/day: take 1 additional dose of 100 mg or 150 mg

* Total dose (mg/day) should be divided according to the treatment regimen mg/dose

Dosage adjustment facilities in patients with renal failure based on creatinine clearance (CLCR), presented in Table 1. To use this dose table, need to calculate the evaluation of creatinine (CLCR) in ml/min from the creatinine level in serum according to the formula of Cockcroft and Gault:

Male: CLCR (ml/min) = weight (kg) x (140 - age): 72 x creatinine serum (mg/100 ml)

Female: ClCr (ml/min) = 0.85 x (above value)

For patients who are causing blood decomposes, pregabalin daily dose should be adjusted depending on the kidney function. In addition to adjusting the daily dose, additional dose should be used immediately after every 4 hours of hemolysis (see Table 1).

What do

do when using overdose? Pregabalin dose is not intentionally highly recorded on clinically 8000 mg, and

No significant clinical consequences. There is no separate antidote for MaxxNeuro. If necessary, indicated to take care

Supporting patient condition includes monitoring of survival signs and observing the patient's clinical status.

can be indicated for hemolysis depending on the clinical condition of patients or in patients with significant renal failure.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that double dose should not be used.

Side Effects

Common, ADR> 1%

Body: abdominal pain, allergic reactions, fever.

Digestive system: Gastritis, increase appetite, dry mouth, constipation, flatulence, vomiting, nausea.

blood vessels and lymph: Bloody.

Nutrition-chemical disorders: peripheral coating, weight gain, coating, fluid retention, hypoglycemia.

Muscle system: joint pain, crust in the legs, muscle pain, muscle weakness; Back pain, muscle spasm.

Nervous system: anxiety, loss of personality, reducing sensation, reducing sexuality, vibration of the eyeball, paresthesia, sedation, bewilderment, convulsions, dizziness, drowsiness, loss of air conditioning, headache, vibration, abnormal thoughts, balance disorders, neurological disorders, abnormal gait, fatigue, weakness, confusion, loss of coordination, dizziness.

Skin and appendages: itching.

The senses: conjunctivitis, double vision, otitis media, tinnitus, blurred vision, laryngeal pain.

Urinary tract system: Disorders of pleasure, impotence, urination, uncontrolled urine.

Uncommon, 1%

Systemic: abscess, cell inflammation, chills, discomfort, stiff neck, pelvic pain, light sensitive reaction.

Cardiovascular system: deep vein embolism, heart failure, hypotension, hypotension posture, retinal blood vessel disorders, fainting.

Gastrointestinal system: cholecystitis, gallstones, colitis, difficulty swallowing, esophagitis, gastritis, gastrointestinal bleeding, black stool, mouth ulcers, pancreatitis, rectal hemorrhage, tongue edema.

Vascular and lymphatic system: Anemia, hyperpassion, blemishes, leukemia, lymph nodes, thrombocytopenia.

Muscle system: joint disease.

Nervous system: abnormal dreams, confusion, apathy, loss of language, abnormalities around the mouth, disorders of language, hallucinations, opposition,

Increased pain, increased sensitivity, hyperactive hyperactivity, reducing tone, increasing sexuality, muscle vibration, neurological pain.

Skin and appendages: baldness, dry skin, eczema, him, skin ulcers, urticaria, bullous rash.

The senses: abnormal adjustments, lash inflammation, dry eyes, eyeball, hearing hyperplasm, fear of light, retinal edema,

loss of taste, taste disorders.

Urinary tract system: abnormal ejaculation, diuretic albumin, amenorrhea, dysmenorrhea, difficult urination, blood urination, kidney stones, white blood, menorrhagia, hemorrhage, glomerulonephritis, urethra, urinary retention, abnormalities in urine.

Rare, ADR

Systemic: anaphylactic reaction, abdominal panel, granuloma, uncomfortable hangover, shock.

Cardiovascular system: St difference, vibration.

Gastrointestinal system: Turian stomatitis, esophageal ulcer, periodontal abscess.

blood vessel and lymphatic system: fibrosis, red blood cells, decreased prothrombin, hemorrhage, platelets.

Nutrition-chemical disorders: Reduce glucose tolerance, urine crystal.

Bone muscle system: cartilage dysplasia, whole spasms.

Nervous system: Addiction, cerebellar syndrome, coma, delusion, illusion, plant neurological disorders, movement disorders, muscular disorders, brain pathology, foreign tower syndrome, Guillain-Barré syndrome, pain reduction, intracranial pressure, abnormal sadness, paranoia, peripheral neuritis, personality disorders, psychological depression, sleep disorders, sleep disorders, stiffness function.

Respiratory system: apnea, bronchitis, hiccups, larynx spasms, pulmonary edema, pulmonary fibrosis, yawning.

Skin and side parts: angioedema, peeling dermatitis, melanoma, nail disease, hemorrhage, itchy rash, skin atrophy, skin necrosis, skin tumor, Stevens-Johnson syndrome.

The senses: irregular pupils, blindness, corneal ulcer, convex eye, paralysis of the muscles outside the bridge, iritis, corneal inflammation, corneal inflammation, pupils, pupils, blindness, longana, ophthalmic atrophy, hemorrhagic nerve atrophy, eagerness, smell, lash collapse, uveitis.

Urinary-sex system: Acute renal failure, foreskin inflammation, bladder tumor, cervicitis, painful intercourse, epididymitis, milk secretion in women, glomerulonephritis, ovarian disorders, pyelonephritis.

Notify the doctor with adverse effects encountered when taking the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Patients with hypersensitivity to pregabalin or any ingredients in the formula.

Be cautious when using

monitor the appearance or deterioration of depression, suicide thoughts, or any other abnormal behaviors.

Monitoring weight gain and/or fluid fluid, may worsen or lead to heart failure. Carefully assess the patient's history of abuse and observe the signs they use wrong or abuse Pregabalin.

Children: Safety and effectiveness have not been verified.

The elderly: Due to the impaired renal function related to age, the dose can be adjusted.

Heart failure: Note when used for heart patients with NYHA III or IV.

Increase the creatine kinase has been recorded. Stop using pregabalin if diagnosis or suspected muscle disease or creatine kinase levels increased significantly.

Clinically significant platelets have been reported.

Stop treatment: Stop the drug slowly (at least 1 week) to minimize the possibility of increasing the frequency of children in convulsions patients. Insomnia, nausea, headache, and diarrhea have been recorded when stopping the drug quickly or suddenly.

Impact on the eye: Reduce vision, market change, and changes when looking at the bottom of the eye has been recorded.

peripheral edema: has been recorded. Often occurs in patients taking pregabalin and diabetes drugs Thiazolidinedione.

extending the PR range (3 to 6 milliseconds) has been recorded; The average difference is not accompanied by an increase in the risk of PR extending PR more than 25% compared to the original, being treating PR more than 200 milliseconds, or increasing the risk of atrial atrial cloned two or three.

The risk of suicidal thoughts or behaviors can be donated. This may appear early in the first week after the beginning of treatment and continue during treatment.

Gain weight has been recorded.

The effect of the drug on the ability to drive and operate machinery

maxxneuro may cause dizziness or drowsiness, blurred vision and other central neurological symptoms, patients are advised not to drive, operate complicated machinery or participate in other adventure activities until determining whether the drug has adverse effects on mental, vision, and/or their actions.

Using drugs for women during pregnancy and lactation

Pregnant women

There are no complete control studies on pregnant women. Do not use Pregabalin during pregnancy unless the benefits give the mother more clearly more important than the risks that may occur to the fetus.

When breastfeeding

It is unknown whether pregabalin is excreted in human milk or not; However, the drug appears in mouse milk. Due to pregabalin's cancer ability in animals, it is important to pay attention to the importance of the drug for mothers to decide to stop breastfeeding or stop taking the drug.

Interactive drug

used with transferred inhibitors (for example, captopril) may increase the risk of angioed and urticaria. Should contact medical staff as soon as these symptoms appear.

Patients need to be treated with central neurological inhibitors (for example, alcohol, Lorazepam, Oxycodone) can see more effects on cognitive and raw motor function. Avoid use with alcohol, beer.

both Pregabalin and Thiazolidinediones (for example, pioglitazone) can cause weight gain and/or fluid, which can be worse or lead to heart failure. Note when using. Monitor the patient. If there is suspicion of drug interactions, may need the dose of one or both drugs.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

To be out of reach of children, read the user manual carefully before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.